Insulin antibodies are often produced in patients with diabetes
treated with insulin preparations. Recombinant human insulin is less
immunogenic than porcine insulin but still produces insulin antibodies
in some patients [1]. Insulin antibodies do not usually cause clinical
symptoms [1] but there are several case reports concerning insulin resistance
[2] or hypoglycemia [3]. Insulin antibodies may reduce insulin
activity by competing for the insulin receptor or the insulin-antibody
complex could work as a pool of insulin, leading to hypoglycemia
upon the release of free insulin [1,4].
Fast-acting insulin analogs, such as insulin lispro (Humalog®) and
insulin aspart (NovoRapid®), and long-acting basal insulin analogs,
such as insulin glargine (Lantus®) and insulin detemir (Levemir®),
are widely used for the treatment of diabetes. To facilitate or delay the
absorbance of insulin, these analogs contain several modifications to